Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes.

Détails

ID Serval
serval:BIB_14FB205C5795
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes.
Périodique
European heart journal
Auteur(s)
Klingenberg R., Aghlmandi S., Liebetrau C., Räber L., Gencer B., Nanchen D., Carballo D., Akhmedov A., Montecucco F., Zoller S., Brokopp C., Heg D., Jüni P., Marti Soler H., Marques-Vidal P.M., Vollenweider P., Dörr O., Rodondi N., Mach F., Windecker S., Landmesser U., von Eckardstein A., Hamm C.W., Matter C.M., Lüscher T.F.
ISSN
1522-9645 (Electronic)
ISSN-L
0195-668X
Statut éditorial
Publié
Date de publication
14/12/2017
Peer-reviewed
Oui
Volume
38
Numéro
47
Pages
3493-3502
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
We aimed to identify a novel biomarker involved in the early events leading to an acute coronary syndrome (ACS) and evaluate its role in diagnosis and risk stratification.
Biomarker identification was based on gene expression profiling. In coronary thrombi of ACS patients, cysteine-rich angiogenic inducer 61 (Cyr61, CCN1) gene transcripts were highly up-regulated compared with peripheral mononuclear cells. In a murine ischaemia-reperfusion model (I/R), myocardial Cyr61 expression was markedly increased compared with the controls. Cyr61 levels were determined in human serum using an enzyme-linked immunosorbent assay. Cohorts of ACS (n = 2168) referred for coronary angiography, stable coronary artery disease (CAD) (n = 53), and hypertrophic obstructive cardiomyopathy (HOCM) patients (n = 15) served to identify and evaluate the diagnostic and prognostic performance of the biomarker. Cyr61 was markedly elevated in ST-elevation myocardial infarction patients compared with non-ST-elevation myocardial infarction/unstable angina or stable CAD patients, irrespective of whether coronary thrombi were present. Cyr61 was rapidly released after occlusion of a septal branch in HOCM patients undergoing transcoronary ablation of septal hypertrophy. Cyr61 improved risk stratification for all-cause mortality when added to the reference GRACE risk score at 30 days (C-statistic 0.88 to 0.89, P = 0.001) and 1 year (C-statistic 0.77 to 0.80, P < 0.001) comparable to high-sensitivity troponin T (30 days: 0.88 to 0.89, P < 0.001; 1 year: 0.77 to 0.79, P < 0.001). Similar results were obtained for the composite endpoint of all-cause mortality or myocardial infarction. Conversely, in a population-based case-control cohort (n = 362), Cyr61 was not associated with adverse outcome.
Cyr61 is a novel early biomarker reflecting myocardial injury that improves risk stratification in ACS patients.

Mots-clé
Acute coronary syndromes, Biomarker, Risk stratification
Pubmed
Web of science
Open Access
Oui
Création de la notice
23/11/2017 20:15
Dernière modification de la notice
20/08/2019 13:43
Données d'usage